No Detail Found!

Bortezomib-based Triplet Regimens for Remission Induction in Multiple Myeloma

Author(s)
Saima Humayun Toor Armed Forces Bone Marrow Transplant Centre / National Institute of Blood and Marrow Transplant,Rawalpindi,Pakistan
Tariq Mahmood Satti Armed Forces Bone Marrow Transplant Centre / National Institute of Blood and Marrow Transplant,Rawalpindi,Pakistan
Raheel Iftikhar Armed Forces Bone Marrow Transplant Centre / National Institute of Blood and Marrow Transplant,Rawalpindi,Pakistan
Syed Kamran Mahmood Armed Forces Bone Marrow Transplant Centre / National Institute of Blood and Marrow Transplant,Rawalpindi,Pakistan
Ghassan Umair Shamshad Armed Forces Bone Marrow Transplant Centre / National Institute of Blood and Marrow Transplant,Rawalpindi,Pakistan
Jahanzeb Ur Rehman Armed Forces Bone Marrow Transplant Centre / National Institute of Blood and Marrow Transplant,Rawalpindi,Pakistan
Abstract
Objective: To compare the e cacy and side e ect pro le of di erent bortezomib-based triplet regimens for remission induction in patients with multiple myeloma (MM). Study design: Observational study. Place and Duration of study: Armed Forces Bone Marrow Transplant Centre, Rawalpindi from January 2014 to December 2018. Methodology: A total of 81 patients of MM, were registered from January 2014 to December 2018. In nal analysis, 44 out of 81 patients were included as per inclusion/exclusion crite.riaBortezomib-based regimens were used either as rst line (in newly diagnosed) or as second line (in relapsed/refractory bortezomib naïve patients) thTehrraepey. di erent bortezomib-based triplet therapies were used (1) VCd, (2) VRd and (3) VTd. As there were only two patients in VTd regimen group so for study purposes VRd and VTd were grouped together, i.e. Vd with an IMiD. Response to treatment was assessed using the IMWG criteria. Comparison between di erent bortezomib-based regimens was performed in terms of their tolerability and response rate after four cycles of chemotherapy. Results: Out of 44 patients, 79.5% (n=35) patients receivedbortezomib-based triplet regimen as rst line therapy, and in 20.5% (n=9) patients as second line therapy. VCd was administered to 56.8% (n=25) and Vd with an IMiD was used in 43.1% (n=19, VRd in 17 and VTd in 2) of the patients. Response was assessed at the end of fourth cycle. Overall response rate was comparable in both groups, 88% in VCd versus 89.4% in Vd with an IMiD group (p=0.432). In VCd and Vd with an IMiD group, CR was observed in 52% (n=13) and 57.9% (n=11) patients, respectively. Disease remained stable in 6.8% (n=3) patients. Treatment was generally well tolerated. Comparative analyses of both treatment groups revealed that the frequency of peripheral neuropathy was signi cantly higher in Vd with an IMiD group (47v.3s%8% p=0.03). Grade III/IV neuropathy observed in 15.7% (n=3) of the patients in Vd with an IMiD groupvs none in VCd group. Grade III/IV cytopenias were more seen in VCd group then in Vd with an IMiD group (16% vs. 5.2% p=0.16). Conclusion: The overall response rates were comparable in VCd and Vd with IMiD, with a better side e ect pro le seen with VCd regimen.
Publication Details
Page(s) 527-531
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 30, Issue: 5, Year: 2020

Request the full text from PASTIC

Keywords
peripheral neuropathy, Triplet therapy, Multiple myeloma, Remission induction, Bortezomib
0

Citations

0

Downloads

107

Views